OXFD - オックスフォ―ド・イミュノテック・グロ―バル (Oxford Immunotec Global PLC)

OXFDのニュース

   Oxford Immunotec Global (NASDAQ:OXFD) Stock Price Passes Below 200 Day Moving Average of $12.57  2020/10/21 02:24:43 US Banking News
Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.57 and traded as low as $11.89. Oxford Immunotec Global shares last traded at $12.03, with a volume of 182,715 shares. Several research analysts have […]
   The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid  2020/06/05 11:34:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.
   KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources  2020/06/04 22:14:00 MarketScreener
By Greg Roumeliotis A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics…
   Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates  2020/05/05 13:15:15 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Oxford Immunotec Global (NASDAQ:OXFD) Stock Price Passes Below 200 Day Moving Average of $12.57  2020/10/21 02:24:43 US Banking News
Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.57 and traded as low as $11.89. Oxford Immunotec Global shares last traded at $12.03, with a volume of 182,715 shares. Several research analysts have […]
   The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid  2020/06/05 11:34:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.
   KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources  2020/06/04 22:14:00 MarketScreener
By Greg Roumeliotis A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics…
   Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates  2020/05/05 13:15:15 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid  2020/06/05 11:34:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.
   KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources  2020/06/04 22:14:00 MarketScreener
By Greg Roumeliotis A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics…
   Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates  2020/05/05 13:15:15 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Richard A. Sandberg Sells 3,000 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock  2019/11/07 15:12:54 Modern Readers
Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. NASDAQ:OXFD opened at $16.72 on Thursday. The company has a quick ratio of 12.76, a current […]

calendar